Italy was studied in detail in a report produced by the Gesundheit Österreich GmbH / Österreichisches Bundesinstitut für Gesundheitswesen (GÖG/ÖBIG – Austrian Health Institute). The report surveyed measures for promoting the rational use of medicines in the 27 EU member states.
Italy’s rational use of medicines
Home/Reports | Posted 08/04/2011 0 Post your comment
Since 2000, the Italian Medicines Agency (Agenzia Italiana del Farmaco, AIFA) has been operating a ‘National Observatory on the Use of Medicines’ (Osservatorio nazionale sull’impiego dei medicinali, OSMED). OSMED monitors and analyses pharmaceutical consumption, e.g. impact of policy measures and comparison to other countries, on a monthly basis. Additionally, yearly reports on pharmaceutical consumption and expenditure are published.
At regular intervals, AIFA runs information campaigns targeted at the general public, e.g. on rational use of antibiotics and promoting generics.
International non-proprietary name prescribing is indicative for doctors and generic substitution is allowed, but not obligatory, for pharmacists in Italy.
Italy has launched a project to trace all medicines brought on to the Italian market, Progetto Tracciabilità del Farmaco, which implied extensive preparatory work (legal framework, IT tools).
Acknowledgement
This article is published with permission of the Gesundheit Österreich GmbH (GÖG)/Austrian Health Institute.
We gratefully acknowledge the support from Dr Sabine Vogler of Gesundheit Österreich GmbH / Österreichisches Bundesinstitut für Gesundheitswesen (GÖG/ÖBIG – Austrian Health Institute) to GaBI Online.
Related articles
The EU and rational use of medicines
Survey on rational use of medicines in 27 EU Members States
The Netherlands and rational use of medicines
France’s rational use of medicines
Rational use of medicines in Denmark
Promoting rational use of medicines in Europe
Germany’s rational use of medicines
Reference
Vogler S, Schmickl B. Rational use of medicines in Europe. Gesundheit Österreich GmbH / Österreichisches Bundesinstitut für Gesundheitswesen (GÖG/ÖBIG). February 2010.
Guidelines
Regulatory update for post-registration of biological products in Brazil
New regulations in Brazil for the registration of biosimilars
Policies & Legislation
NPRA Malaysia trials new timelines for variation applications
Regulatory evolution and impact of simplified requirements for interchangeable biosimilars in the US
Comments (0)
Post your comment